Senses Disorder TRIZ Cases

Humanized anti-α2 integrin antibodies bind the I domain to inhibit collagen interaction without activating platelets, resolving bleeding risks.

Energy modulation agents convert deep-penetrating initiation light into activation energy to selectively modify diseased cells while sparing healthy tissue.

Merges Rho kinase and carbonic anhydrase inhibitors into a single preparation to extend ocular hypotensive duration beyond single-drug limits.

Daily omega-3 triglyceride supplementation modifies meibum lipid composition to address chronic inflammation and inadequate tear film quality.

Transcription factor expression drives corneal endothelial progenitor differentiation to resolve donor tissue shortages and ensure consistent cell quality.

Specific guide RNA directs Cas9 nuclease to cleave mutant CYP4V2 sequences, resolving competitive inhibition from existing mutant products.

SOUL opsin achieves deep brain modulation by using red-shifted wavelengths and prolonged kinetics to overcome light attenuation without surgical implants.

A linker fragment comprising three Cys residues forms disulfide bonds, stabilizing the Fc fusion protein at low pH during purification.

Formula I compounds inhibit glucagon-induced glucose excursion, resolving the lack of effective receptor antagonism in current diabetes therapies.

A water-in-oil emulsion provides sustained release of hydrophilic therapeutic agents via buoyant bubble migration.

Alpha-methyl substituted diazabicyclo-[4.3.1]-decane derivatives inhibit FKBP proteins with high binding affinity.

Sucrose and buffering agents stabilize AAV formulations at -20 C, preventing crystallization and degradation.

15-nitrooxyderivatives of latanoprost reduce intraocular pressure while minimizing ocular side effects via composite material principles.

Amphiphilic triblock copolymers form micelles or thermo-reversible gels to encapsulate therapeutically active agents while eliminating organic solvent residues.

Novel small molecule TLR2 antagonists enable oral administration through high bioavailability and IL-8 secretion inhibition.

An AAV5 vector with a modified GFAP promoter targets optic nerve head astrocytes, bypassing daily eye drop adherence for sustained glaucoma treatment.

Hydrophilic ester prodrugs balance hydrophobic and hydrophilic properties to enhance corneal penetration.

Ionized salt forms of 1,2,4-oxadiazole benzoic acid reduce eye irritation and improve solubility via buffering systems.

Humanized antibodies bind the tenascin-C fibrinogen-like globe domain to neutralize inflammatory activity.

Ophthalmic composition with gold nanoparticles and antioxidative ingredients delivers targeted protection to the eye surface.

Formula I compounds inhibit GlyT1 to increase synaptic glycine, addressing cognitive deficits unresponsive to dopamine therapies.

Formaldehyde releasing agents cross-link corneal collagen to prevent progressive thinning and vision loss in keratoconus treatment.

Adeno-associated viral vectors deliver functional TMPRSS3 genes to restore inner ear hair cell activity.

A humanized non-IgG1 antibody modulates p38 MAPK activation in microglia cells to reduce amyloid plaque formation.

HEPES buffer stabilizes anakinra protein formulations, reducing local irritation and degradation during storage.

Segmented Formula I compounds inhibit unregulated tyrosine kinase signal transduction to treat cancers and neurodegenerative diseases.

Coenzyme Q10 compounds traverse the blood-brain barrier to reduce tumor size while sparing surrounding healthy brain tissue from damage.

Substituted N-phenylacetamides inhibit P2X4 receptors, providing targeted relief from dry eye syndrome and post-operative ocular pain.

A phosphorylated polypeptide downregulates integrins and MMP2 to inhibit angiogenesis.

O-substituted hydroxyalkyl radicals on aromatic rings increase aqueous solubility of retinoid compounds, resolving formulation constraints.

Monocyclic heterocyclic compound blocks S1P-Edg-1 binding, resolving lack of novel skeleton for autoimmune disease treatment.

Quinoxalinone derivatives restore glucose-induced insulin secretion, reducing hypoglycemia risk and beta cell exhaustion in type 2 diabetes.

Specific ALDH2 modulating compounds reduce aldehyde levels to treat alcohol-related disorders and cancer.

Liposomes encapsulate bicelles to prevent morphological transformation into larger vesicles in high-water environments, maintaining permeability.

Acylamino-substituted cyclic carboxylic acid derivatives inhibit the Edg-2 receptor to block lysophosphatidic acid signaling pathways.

A transmucosal composition containing oxidized and reduced coenzyme Q10 enables direct mucosal absorption.

A cryopreservation medium containing 2% dimethylsulfoxide and 6% hydroxyethyl starch preserves viable cells during freezing.

Synthetic peptide amides act as selective kappa opioid receptor agonists to deliver targeted pain relief while minimizing central nervous system side effects.

Dasatinib polymorphs resolve industrial production bottlenecks by reducing organic solvent usage through controlled crystallization conditions.

Mechanical stimulation and chemical stress induce somatic cells to assume a pluripotent state without exogenous genetic material.

Modified macrolides inhibit phosphodiesterase 4 to treat inflammatory diseases without antibiotic resistance or emesis side effects.

A clear aqueous liquid preparation maintains optical clarity through precise preservative concentration management.